MWC Barcelona 2025: Fibocom Launches Qualcomm X85/X82 5G Modem-RF-Powered 5G Modules, Enhancing FWA AI Capabilities
BARCELONA, Spain, March 4, 2025 /PRNewswire/ -- Fibocom (Stock code:300638), a global leading provider of AIoT solutions and wireless communication modules, announced the launch of its new 5G modules and solutions based on Qualcomm Technologies,...
CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong
DALIAN, China, March 3, 2025 /PRNewswire/ -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy", or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced its participation in the...
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced...
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...
Metanoia Unveils MT5824: The World's Lowest Power, Smallest Footprint 4T4R O-RU Solution
TAIPEI, Feb. 27, 2025 /PRNewswire/ -- At Mobile World Congress (MWC) 2025, Metanoia will showcase the MT5824 chipset, a groundbreaking 5G SoC with future-proof Software Defined Radio (SDR) architecture, open-source flexibility, and industry-leading...
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and...
Ascenda and Galileo Financial Technologies Collaborate to Elevate Card Loyalty Programs
Partnership combines Galileo's technology platform and Ascenda's loyalty expertise to simplify and power card loyalty programs NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Ascenda, the industry leader in loyalty-as-a-service, has partnered with Galileo...
ZTO to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 18, 2025 U.S. Eastern Time
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company"), a leading and fast-growing express delivery company in China, today announced that it will release its unaudited financial results...
ALL INDIVIDUALS WHO PURCHASED OR ACQUIRED IMPACT THEORY FOUNDER'S KEYS BETWEEN OCTOBER 13, 2021, AND DECEMBER 6, 2021
COSTA MESA, Calif., Feb. 24, 2025 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc., Fund Administrator for the United States Securities and Exchange Commission, regarding the Impact Theory Fair Fund and Plan of...
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile,...